Latest News



Meet CTC at The future of Swedish & Danish Life Science, 31 March 2016

CTC will attend the future of Swedish & Danish Life Science next week. Anders (CEO), Bengt (CSO) and Tina (Director PM) will attend the meeting - just send me an email or give me a call if you want to meet! See you in Lund. 


CTC Clinical Trial Consultants AB fortsätter att expandera

CTC AB har sedan starten för 5 år sedan kraftigt expanderat verksamheten från 1,6 till 32 MSEK i årsomsättning. CTC har nyligen genomfört en riktad nyemission för att skapa förutsättningar för fortsatt expansion av verksamheten och i samband med detta bildat holdingbolaget Center for Translational Research AB som äger 100% av CTC AB. De tidigare delägarna i CTC AB är majoritetsägare i Center for Translational Research AB.


CTC AB är ett specialist CRO med fokus på det kliniska genomförandet av kliniska prövningar i tidig fas (fas 0, I och IIa) både på friska frivilliga och patienter vid CTCs centralt belägna forskningsklinik på Akademiska sjukhuset i Uppsala.

CTC AB driver också två specialistmottagningar för Fas II-IV studier i Uppsala och Linköping.

För information

Styrelseordförande Bengt Dahlström,

tel: 0703-10 85 87, email:


Klaria AB ett steg närmare klinisk prövning på produkten KL-00119 mot migrän


CTC sponsor of Almtuna Team 04:s cup


CTC in Collaboration with Klaria Pharma Holding AB


NLS 2015 - Stockholm

Meet Anders, Tina and Bengt at the Nordic Life Science Day´s in Stockholm 9 - 10 Sep 2015. Wanna talk about early phase trials, you can find us in our exhibition stand. Look for the flag "PHASE 1", see you there!  


New Scientific Advisor at CTC - Professor Claes Post

Claes Post is Master of Pharmacy from Uppsala university, Pharm Dr from Linköping university, Associate Professor in Neuropharmacology and Anesthesiology from Uppsala university, previously Professor (Adjunct) in Neuropharmacology at Uppsala university, Lund university and Karolinska Institute. Currently he is Guest Professor in Neuropharmacology at Linköping university. After his Pharm Dr, he did a post-doctoral at NIH (NIEHS) in the USA. From 1981 – 1994 he was scientist and Preclinical vice president at Astra Pain Control and Astra Draco. Between 1994 and 1997 Claes was senior vice president for preclinical and clinical CNS drug discovery and development, as well as medical director CNS. He has been CEO of several start-up companies in the pharmaceutical fiels, for example Melacure Therapeutics (Uppsala), Gastrotech (Copenhagen, Denmark), and Aprea (Stockholm). Claes has also been engaged in university based technology transfer as, as CEO of Karolinska Innovations AB, and senior business development at Linköping university. Currently Claes is Investment manager in the Life Science field at ALMI INVEST AB and serves as member of Boards at several ALMI INVEST Portfolio companies. Academically he has published more than 140 articles in peer review scientific journals.


Dag Nyholm - Combined treatment of Parkinson´s - Clinical conduct at CTC

View the folloiwng link, this study is performed at CTC´s hospital based clinic in Uppsala (Akademiska Sjukhuset)


CTC is looking for a phase 1 project manager

We are currently looking for a project mananger,


Johan Gabrielsson Scientific Advisor at CTC

Johan Gabrielsson has been added as Scientific Advisor at CTC.

Page 3 of 5 pages  < 1 2 3 4 5 >